首页> 美国卫生研究院文献>other >Allergen-Specific Antibodies Regulate Secondary Allergen-Specific Immune Responses
【2h】

Allergen-Specific Antibodies Regulate Secondary Allergen-Specific Immune Responses

机译:过敏原特异性抗体可调节继发性过敏原特异性免疫反应

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Immunoglobulin E (IgE)-associated allergy is the most common immunologically-mediated hypersensensitivity disease. It is based on the production of IgE antibodies and T cell responses against per se innocuous antigens (i.e., allergens) and subsequent allergen-induced inflammation in genetically pre-disposed individuals. While allergen exposure in sensitized subjects mainly boosts IgE production and T cell activation, successful allergen-specific immunotherapy (AIT) induces the production of allergen-specific IgG antibodies and reduces T cell activity. Under both circumstances, the resulting allergen-antibody complexes play a major role in modulating secondary allergen-specific immune responses: Allergen-IgE complexes induce mast cell and basophil activation and perpetuate allergen-specific T cell responses via presentation of allergen by allergen presenting cells to T cells, a process called IgE-facilitated antigen presentation (FAP). In addition, they may induce activation of IgE memory B cells. Allergen-induced production of specific IgGs usually exerts ameliorating effects but under certain circumstances may also contribute to exacerbation. Allergen-specific IgG antibodies induced by AIT which compete with IgE for allergen binding (i.e., blocking IgG) inhibit formation of IgE-allergen complexes and reduce activation of effector cells, B cells and indirectly T cells as FAP is prevented. Experimental data provide evidence that by binding of allergen-specific IgG to epitopes different from those recognized by IgE, allergen-specific IgG may enhance IgE-mediated activation of mast cells, basophils and allergen-specific IgE+ B cells. In this review we provide an overview about the role of allergen-specific antibodies in regulating secondary allergen-specific immune responses.
机译:免疫球蛋白E(IgE)相关的过敏是最常见的免疫介导的超敏性疾病。它基于IgE抗体的产生和针对本身无害抗原(即变应原)的T细胞反应以及随后在遗传易感个体中由变应原诱发的炎症。致敏对象中的过敏原暴露主要促进IgE产生和T细胞活化,成功的过敏原特异性免疫疗法(AIT)诱导产生过敏原特异性IgG抗体并降低T细胞活性。在这两种情况下,所得的过敏原-抗体复合物在调节次级过敏原特异性免疫反应中起主要作用:过敏原-IgE复合物诱导肥大细胞和嗜碱性粒细胞活化,并通过由过敏原呈递细胞向过敏原呈递来使过敏原特异性T细胞应答持久化。 T细胞,称为IgE促进抗原呈递(FAP)的过程。另外,它们可能诱导IgE记忆B细胞活化。变应原诱导的特异性IgG产生通常可以改善症状,但在某些情况下也可能加剧病情。由AIT诱导的与IgE竞争变应原结合(即阻断IgG)的变应原特异性IgG抗体抑制了IgE-变应原复合物的形成,并减少了FAP阻止的效应细胞,B细胞和间接T细胞的活化。实验数据提供了证据,即通过将过敏原特异性IgG与不同于IgE识别的抗原决定簇结合,过敏原特异性IgG可以增强IgE介导的肥大细胞,嗜碱性粒细胞和过敏原特异性IgE + B的激活。细胞。在这篇综述中,我们提供了有关过敏原特异性抗体在调节继发性过敏原特异性免疫反应中的作用的概述。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号